Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	BOUDNÝ Miroslav ZEMANOVÁ Jana KHIRSARIYA PrashantKumar BORSKÝ Marek VERNER Jan ČERNÁ Jana MRÁZ Marek OLTOVÁ Alexandra JAŠKOVÁ Zuzana ŠPUNAROVÁ Michaela ŠEDA Václav BRYCHTOVÁ Yvona MAYER Jiří PARUCH Kamil TRBUŠEK Martin
Year of publication	2018
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations, Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations.
Related projects:	Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit V